1
|
Pardo-Rodriguez D, Lasso P, Santamaría-Torres M, Cala MP, Puerta CJ, Méndez Arteaga JJ, Robles J, Cuervo C. Clethra fimbriata hexanic extract triggers alteration in the energy metabolism in epimastigotes of Trypanosoma cruzi. Front Mol Biosci 2023; 10:1206074. [PMID: 37818099 PMCID: PMC10561390 DOI: 10.3389/fmolb.2023.1206074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2023] [Accepted: 09/13/2023] [Indexed: 10/12/2023] Open
Abstract
Chagas disease (ChD), caused by Trypanosoma cruzi, is endemic in American countries and an estimated 8 million people worldwide are chronically infected. Currently, only two drugs are available for therapeutic use against T. cruzi and their use is controversial due to several disadvantages associated with side effects and low compliance with treatment. Therefore, there is a need to search for new tripanocidal agents. Natural products have been considered a potential innovative source of effective and selective agents for drug development to treat T. cruzi infection. Recently, our research group showed that hexanic extract from Clethra fimbriata (CFHEX) exhibits anti-parasitic activity against all stages of T. cruzi parasite, being apoptosis the main cell death mechanism in both epimastigotes and trypomastigotes stages. With the aim of deepening the understanding of the mechanisms of death induced by CFHEX, the metabolic alterations elicited after treatment using a multiplatform metabolomics analysis (RP/HILIC-LC-QTOF-MS and GC-QTOF-MS) were performed. A total of 154 altered compounds were found significant in the treated parasites corresponding to amino acids (Arginine, threonine, cysteine, methionine, glycine, valine, proline, isoleucine, alanine, leucine, glutamic acid, and serine), fatty acids (stearic acid), glycerophospholipids (phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine), sulfur compounds (trypanothione) and carboxylic acids (pyruvate and phosphoenolpyruvate). The most affected metabolic pathways were mainly related to energy metabolism, which was found to be decrease during the evaluated treatment time. Further, exogenous compounds of the triterpene type (betulinic, ursolic and pomolic acid) previously described in C. fimbriata were found inside the treated parasites. Our findings suggest that triterpene-type compounds may contribute to the activity of CFHEX by altering essential processes in the parasite.
Collapse
Affiliation(s)
- Daniel Pardo-Rodriguez
- Grupo de Enfermedades Infecciosas, Pontificia Universidad Javeriana, Bogotá, Colombia
- Grupo de Fitoquímica, Pontificia Universidad Javeriana, Bogotá, Colombia
- Grupo de Productos Naturales, Universidad del Tolima, Tolima, Colombia
- Metabolomics Core Facility—MetCore, Vice-Presidency for Research, Universidad de los Andes, Bogotá, Colombia
| | - Paola Lasso
- Grupo de Inmunobiología y Biología Celular, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Mary Santamaría-Torres
- Metabolomics Core Facility—MetCore, Vice-Presidency for Research, Universidad de los Andes, Bogotá, Colombia
| | - Mónica P. Cala
- Metabolomics Core Facility—MetCore, Vice-Presidency for Research, Universidad de los Andes, Bogotá, Colombia
| | - Concepción J. Puerta
- Grupo de Enfermedades Infecciosas, Pontificia Universidad Javeriana, Bogotá, Colombia
| | | | - Jorge Robles
- Grupo de Fitoquímica, Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Claudia Cuervo
- Grupo de Enfermedades Infecciosas, Pontificia Universidad Javeriana, Bogotá, Colombia
| |
Collapse
|
2
|
Dudzik D, Iglesias Platas I, Izquierdo Renau M, Balcells Esponera C, del Rey Hurtado de Mendoza B, Lerin C, Ramón-Krauel M, Barbas C. Plasma Metabolome Alterations Associated with Extrauterine Growth Restriction. Nutrients 2020; 12:E1188. [PMID: 32340341 PMCID: PMC7230608 DOI: 10.3390/nu12041188] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 04/15/2020] [Accepted: 04/21/2020] [Indexed: 12/14/2022] Open
Abstract
Very preterm infants (VPI, born at or before 32 weeks of gestation) are at risk of adverse health outcomes, from which they might be partially protected with appropriate postnatal nutrition and growth. Metabolic processes or biochemical markers associated to extrauterine growth restriction (EUGR) have not been identified. We applied untargeted metabolomics to plasma samples of VPI with adequate weight for gestational age at birth and with different growth trajectories (29 well-grown, 22 EUGR) at the time of hospital discharge. A multivariate analysis showed significantly higher levels of amino-acids in well-grown patients. Other metabolites were also identified as statistically significant in the comparison between groups. Relevant differences (with corrections for multiple comparison) were found in levels of glycerophospholipids, sphingolipids and other lipids. Levels of many of the biochemical species decreased progressively as the level of growth restriction increased in severity. In conclusion, an untargeted metabolomic approach uncovered previously unknown differences in the levels of a range of plasma metabolites between well grown and EUGR infants at the time of discharge. Our findings open speculation about pathways involved in growth failure in preterm infants and the long-term relevance of this metabolic differences, as well as helping in the definition of potential biomarkers.
Collapse
Affiliation(s)
- Danuta Dudzik
- Centro deMetabolómica y Bioanálisis, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, 28660 Madrid, Spain or
- Department of Biopharmaceutics and Pharmacodynamics, Faculty of Pharmacy, Medical University of Gdansk, 80-416 Gdańsk, Poland
| | - Isabel Iglesias Platas
- Neonatal Unit, BCNatal, Hospital Sant Joan de Déu i Clínic, Barcelona University, 08950 Barcelona, Spain; (M.I.R.); (C.B.E.); (B.d.R.H.d.M.)
- Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain; (C.L.); (M.R.-K.)
| | - Montserrat Izquierdo Renau
- Neonatal Unit, BCNatal, Hospital Sant Joan de Déu i Clínic, Barcelona University, 08950 Barcelona, Spain; (M.I.R.); (C.B.E.); (B.d.R.H.d.M.)
- Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain; (C.L.); (M.R.-K.)
| | - Carla Balcells Esponera
- Neonatal Unit, BCNatal, Hospital Sant Joan de Déu i Clínic, Barcelona University, 08950 Barcelona, Spain; (M.I.R.); (C.B.E.); (B.d.R.H.d.M.)
- Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain; (C.L.); (M.R.-K.)
| | - Beatriz del Rey Hurtado de Mendoza
- Neonatal Unit, BCNatal, Hospital Sant Joan de Déu i Clínic, Barcelona University, 08950 Barcelona, Spain; (M.I.R.); (C.B.E.); (B.d.R.H.d.M.)
- Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain; (C.L.); (M.R.-K.)
| | - Carles Lerin
- Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain; (C.L.); (M.R.-K.)
- Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
| | - Marta Ramón-Krauel
- Institut de Recerca Sant Joan de Déu, 08950 Barcelona, Spain; (C.L.); (M.R.-K.)
- Endocrinology Department, Hospital Sant Joan de Déu, 08950 Barcelona, Spain
| | - Coral Barbas
- Centro deMetabolómica y Bioanálisis, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, 28660 Madrid, Spain or
| |
Collapse
|